Buy PNC-27 (10mg)
PNC-27 Product Description
PNC-27 is a synthetic peptide designed to selectively kill cancer cells by targeting a protein called HDM-2 (also known as MDM2) found on the membranes of many cancer cells. It works by binding to membrane-bound HDM-2, forming pores in the cancer cell membrane, and causing rapid cell death through necrosis, while sparing normal cells.
PNC-27 is derived from the p53 protein’s HDM-2 binding domain (amino acids 12-26) and is linked to a membrane-penetrating sequence, allowing it to enter and act on cancer cell membranes. The peptide binds specifically to HDM-2 present on the surface of cancer cells, not normal cells. This binding leads to the formation of transmembrane pores, disrupting the cell membrane and causing cell lysis and necrosis, independent of the p53 pathway.
Peptide Information
| Property | Value |
|---|---|
| Peptide Sequence | Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly |
| Molecular Formula | C188H293N53O44S |
| Molecular Weight | 4029.2 g/mol |
| CAS Number | 1159861-00-3 |
| Synonyms | H-PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG-OH, PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG-acid, H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH, A6, Paralit |
PNC-27 Peptide Structure
Source: PubChem
Lyophilized Peptides:
These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.
Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug.
PNC-27 Research
PNC-27 research has focused on its mechanism of action, selectivity for cancer cells, and potential as a broad-spectrum anti-cancer agent, including its effects on primary tumors and chemoresistant cancers.
Membrane Pore Formation
PNC-27 contains a segment from the p53 protein that binds to HDM-2 on cancer cell membranes. This binding leads to the formation of transmembrane pores, causing rapid necrosis of cancer cells by allowing cell contents to leak out.[1] The peptide forms 1:1 complexes with HDM-2, which then dimerize to create these pores.[1]
Selectivity for Cancer Cells
PNC-27 targets cancer cells because they express high levels of membrane-bound HDM-2, unlike normal cells, which have little or none. This selectivity results in minimal toxicity to normal cells, including hematopoietic stem cells and other non-cancerous tissues.[1]
Broad Anticancer Activity
PNC-27 has demonstrated cytotoxicity against a wide range of solid and hematopoietic tumors, including chemotherapy-resistant cancers and primary tumor cells from ovarian and uterine cancers. The anticancer peptide has also shown efficacy in animal models, eradicating metastatic pancreatic tumors and leukemia stem cells. [1][2][3]
Primary Tumor Studies
Ex vivo studies on freshly isolated primary human ovarian and uterine cancer cells confirmed that PNC-27 induces dose-dependent cell death, with no observed effect on normal cells.[2]
References
- Pincus, M., Silberstein, M., Zohar, N., Sarafraz‐Yazdi, E., & Bowne, W. (2024). Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines, 12. https://doi.org/10.3390/biomedicines12061144.
- Sarafraz‐Yazdi, E., Salame, G., Gorelick, C., Wagreich, A., Angert, M., Abulafia, O., Pincus, M., & Michl, J. (2011). Abstract C44: Ex vivo cytotoxicity of PNC-27 on primary human ovarian and endometrial cancers. Cancer Research, 71. https://doi.org/10.1158/1538-7445.FBCR11-C44.
- Wang, H., Zhao, D., Nguyen, L., Wu, H., Li, L., Dong, D., Troadec, E., Zhu, Y., Hoang, D., Stein, A., Malki, M., Aldoss, I., Lin, A., Ghoda, L., McDonald, T., Pichiorri, F., Carlesso, N., Kuo, Y., Zhang, B., Jin, J., & Marcucci, G. (2019). Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia, 34, 75-86. https://doi.org/10.1038/s41375-019-0522-9.
Endotoxin PNC-27
PNC-27 (11359)
PNC-27 (251520)
PNC-27 (251520E)
×
Disclaimer: For Research Purposes Only
This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides. . .
Related products
